Ontruzant (trastuzumab-dttb), a biosimilar to Genentech‘s Herceptin (trastuzumab), will now be made available in the U.S. as a treatment for HER2-overexpressing breast cancers as well as for stomach cancers, according to a press release from Merck. Merck will be launching the antibody treatment in the U.S., as part of an agreement with Samsung Bioepis, Ontruzant’s developers. It will be available for the same indications as Herceptin. The U.S. Food and Drug Administration (FDA) had approved the biosimilar…
You must be logged in to read/download the full post.
The post Merck to Launch Ontruzant, a Herceptin Biosimilar, in US appeared first on BioNewsFeeds.